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ABSTRACT
Introduction Diabetes is observed to increase cancer 
risk, leading to hypothesized direct effects of either 
hyperglycemia or medication. We investigated associations 
between glycosylated hemoglobin (HbA1c) across the 
whole glycemic spectrum and incidence of 16 cancers in a 
population sample with comprehensive adjustment for risk 
factors and medication.
Research design and methods Linked data from the 
UK Biobank and UK cancer registry for all individuals with 
baseline HbA1c and no history of cancer at enrollment 
were used. Incident cancer was based on International 
Classification of Diseases – 10th Edition diagnostic codes. 
Age- standardized incidence rates were estimated by 
HbA1c category. Associations between HbA1c, modeled as 
a restricted cubic spline, and cancer risk were estimated 
using Cox proportional hazards models.
Results Among 378 253 individuals with average follow- 
up of 7.1 years, 21 172 incident cancers occurred. While 
incidence for many of the 16 cancers was associated 
with hyperglycemia in crude analyses, these associations 
disappeared after multivariable adjustment, except for 
pancreatic cancer (HR 1.55, 95% CI 1.22 to 1.98 for 55 vs 
35 mmol/mol), and a novel finding of an inverse association 
between HbA1c and premenopausal breast cancer (HR 
1.27, 95% CI 1.00 to 1.60 for 25 vs 35 mmol/mol; HR 0.71, 
95% CI 0.54 to 0.94 for 45 vs 35 mmol/mol), not observed 
for postmenopausal breast cancer. Adjustment for diabetes 
medications had no appreciable impact on HRs for cancer.
Conclusions Apart from pancreatic cancer, we did 
not demonstrate any independent positive association 
between HbA1c and cancer risk. These findings suggest 
that the potential for a cancer- inducing, direct effect of 
hyperglycemia may be misplaced.
INTRODUCTION
Multiple observational studies have shown 
an increased risk of many cancer types in 
people with diabetes, independent of body 
mass index (BMI).1 2 The reasons for this are 
not fully understood but may include direct 
effects of hyperglycemia, insulin resistance, 
genetic risk, chronic inflammation or other 
associated metabolic abnormalities.3 Alterna-
tively, effects of glucose- lowering medication 
may account for excess risks of cancer in asso-
ciation with diabetes.3
Studying cancer risk across the entire 
glycemic spectrum may help distinguish 
between medication and underlying disease- 
related effects. Recent systematic reviews are 
conflicting, postulating positive, U- shaped 
and null associations between glycosylated 
hemoglobin (HbA1c) and overall cancer 
incidence.4 5 Such conflicting findings may, 
in part, be due to small numbers, especially 
for those without diabetes. Furthermore, 
relationships between HbA1c and cancer 
may differ by cancer site.6 More recently, 
Dankner et al7 studied 440 000 individuals 
with type 2 diabetes, including over 20 000 
incident cancer cases during follow- up. The 
authors observed no evidence of association 
Significance of this study
What is already known about this subject?
 ► Diabetes has been associated with increased cancer 
risk.
What are the new findings?
 ► This study is the largest to date to investigate the as-
sociation between glycosylated hemoglobin (HbA1c) 
and 16 specific cancers adjusting for a wide range of 
demographic, lifestyle, and clinical factors.
 ► We found no consistent evidence that higher HbA1c 
was associated with incident cancer risk apart from 
pancreatic cancer.
 ► A novel finding was an inverse association between 
HbA1c and premenopausal breast cancer, which 
persisted when people with diagnosed diabetes or 
on glucose- lowering medications were excluded.
How might these results change the focus of 
research or clinical practice?
 ► Concerns around the potential for a cancer- inducing, 
direct effect of hyperglycemia may be misplaced.
 ► Future research should focus on other potential 
mechanisms that may explain the association be-
tween diabetes and cancer.
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between poor glycemic control and cancer risk except for 
an adverse effect on pancreatic cancer and a protective 
effect for prostate cancer.
Large numbers of individuals without diabetes or not 
considered to be at high risk for diabetes are unlikely 
to have measurements of glycemic status such as HbA1c 
in routine care. However, UK Biobank collected HbA1c 
measurements at recruitment on ~500 000 partici-
pants, regardless of diabetes status, presenting a unique 
opportunity to study associations with health across the 
glycemic spectrum. We studied the association between 
HbA1c and incidence of 16 site- specific cancers within 
UK Biobank, both in the overall cohort and in those 
without a diabetes diagnosis, to help disentangle the 
effects of glycemic status from any effect(s) of glucose- 
lowering medications.
DESIGN AND STUDY METHODS
Study population
Full details of the UK Biobank cohort have been previ-
ously described.8 9 Briefly, the UK Biobank includes 
502 536 men and women aged 40–69 years recruited 
between 2006 and 2010 from primary care practices in 
England, Scotland, and Wales. Participants underwent 
a baseline assessment capturing sociodemographic and 
lifestyle factors, health status, and gave blood samples for 
biomarker measurement. Participants also consented for 
linkage to electronic medical records including national 
cancer and death registries. All participants were eligible 
for this study. We excluded individuals with a history 
of any cancer (excluding non- melanoma skin cancer 
(NMSC)) at baseline, either via self- report at baseline 
assessment under consultation with a trained nurse or via 
linked cancer registry records.
Study period
Baseline for this study was defined as the date of base-
line assessment. Participants were considered at risk from 
6 months after baseline to reduce the impact of reverse 
causality among cancers diagnosed shortly after baseline, 
whereby the undiagnosed cancer may have affected the 
baseline HbA1c measurement. Follow- up ended at the 
earliest of: first record of any cancer (as defined below), 
last date of coverage for the cancer registry (March 2016 
in England and Wales; October 2015 in Scotland), or date 
of death. For premenopausal breast cancer outcomes, 
participants were additionally censored at age 55 years.
Exposure
HbA1c (mmol/mol) was measured using high- 
performance liquid chromatography from blood samples 
taken at baseline. A total of 33 104 (7%) of participants 
had missing values returned, with 14 565 (44%) of these 
related to assay failure or dilution factors. Values above 
200 mmol/mol were considered outliers and excluded 
from the analysis.
Cancer outcomes
Cancer incidence was defined as the first occurrence of 
an International Classification of Diseases – 10th Edition 
(ICD-10) code for malignant cancer (ICD-10 Chapter 
C) excluding NMSC (C44) from the cancer registry. We 
also considered deaths for which cancer was a primary or 
contributing cause of death as incident cancer if there 
was no preceding record in the cancer registry.
The four most common cancers in the cohort were 
considered primary outcomes of interest, including pros-
tate (C61), breast (C50), colorectal (C18–C20) and lung 
(C34). Breast cancers were analyzed separately by meno-
pausal status. Postmenopausal status was defined as either 
age 55 years or older, or taking hormone replacement 
therapy (HRT), consistent with previous literature.10 We 
also examined 12 secondary cancer outcomes that were 
less common in the cohort: esophageal (C15), stomach 
(C16), pancreatic cancer (C25), melanoma (C43), 
uterus (C54–55), ovarian (C56), kidney (C64), bladder 
(C67), central nervous system (C71–72), non- Hodgkin’s 
lymphoma (C82–85), multiple myeloma (C90), and 
leukemia (C91–94).
Covariates
We extracted the following variables from the baseline 
assessment data: demographic and socioeconomic factors 
(age, sex, ethnicity and Townsend deprivation index); 
BMI; physical activity (number of days per week engaging 
in more than 10 min of walking, moderate and vigorous 
physical activity); lifestyle behaviors (smoking status and 
alcohol consumption); dietary intake (processed meat, 
fruits and vegetables); use of medications (such antidi-
abetic therapy, HRT, and oral contraceptives); and diag-
noses of comorbidities (cardiovascular disease and types 
1 and 2 diabetes). Rate of smoking among current or 
former smokers was categorized as 1–9, 10–19, 20–29, 
and 30+ cigarettes smoked per day. We used a previously 
validated algorithm to identify diagnosed types 1 and 2 
diabetes, which included exposure to glucose- lowering 
therapies.11
Among 467 456 participants eligible for study inclu-
sion, 89 203 (19%) had missing baseline data. A large 
proportion of missingness was driven by lack of baseline 
HbA1c (n=33 104, 7%), self- reported physical activity 
measures (n=36 654, 8%), and self- reported smoking or 
alcohol measures (n=15 652, 3%) (figure 1). Reasons for 
missing baseline HbA1c included laboratory reporting 
and data issues (70%) and therefore largely missing at 
random, while the remaining 30% were missing for 
some unknown reason. Lifestyle measures were missing 
because participants responded, ‘prefers not to say’, thus 
likely missing not at random.
Statistical analysis
For descriptive analyses of covariates and cancer inci-
dence rates, HbA1c was categorized at standard clinical 
cut- off points for normal glycemia (<6% or <42 mmol/
mol), prediabetes (6%–6.4% or 42–47 mmol/mol) and 
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diabetes (≥6.5% or ≥48 mmol/mol), irrespective of diag-
nosed diabetes status at recruitment. Incidence rates for 
each cancer were estimated by HbA1c category and age 
standardized to the UK Biobank population. Percen-
tile CIs were estimated using 500 bootstrap replications 
since traditional methods are unable handle non- integer 
denominators.
For all other analyses, HbA1c was treated as a contin-
uous variable modeled as a restricted cubic spline with 
knots at 4.4%, 5.4%, and 6.3% (25, 35, and 45 mmol/
mol). We centred these parameters around 5.4% (35 
mmol/mol)—the median value for those in the normal 
glycemia category—to provide a relevant reference value. 
HRs and 95% CI for the effect of HbA1c on cancer inci-
dence were estimated using Cox proportional hazards 
models using time since baseline as the time scale. 
Likelihood ratio tests were used to assess the overall 
effect of HbA1c and any evidence of non- linearity. The 
proportional hazards assumption was tested by inspecting 
whether scaled Schoenfeld residuals were independent 
of time.
All models were adjusted for the available known risk 
factors for cancer that are also likely to influence HbA1c, 
namely, age, sex (except sex- specific cancers), ethnicity, 
deprivation, BMI, physical activity, cardiovascular and 
diabetes diagnoses at baseline, smoking status, and 
alcohol consumption. Analyses of breast, uterus, and 
ovarian cancers were additionally adjusted for use of HRT 
(postmenopausal only) and oral contraceptives. Anal-
yses of colorectal and stomach cancers were additionally 
adjusted for dietary intake. Analyses of lung, esophageal, 
and stomach cancers were additionally adjusted for age 
at start and stop of smoking among former smokers and 
rate of smoking among current smokers. All models were 
then refitted on the sample restricted to those without a 
diagnosis of diabetes at baseline to examine the effect of 
HbA1c in the absence of long- term exposure to glucose- 
lowering medications. A small number of individuals 
(n=128) on metformin for other indications were also 
excluded.
We used complete case analysis because a large propor-
tion of missingness was likely to be missing not at random. 
In this circumstance, although multiple imputation is not 
appropriate, a complete case analysis will be unbiased if, 
conditional on model covariates, missingness is indepen-
dent of the outcome.12
Sensitivity analyses
First, we investigated whether the effect of HbA1c on 
risk of cancer differed in a subgroup without smoking 
history, a key risk factor for many of the included cancer 
outcomes. Second, we assessed the potential for reverse 
causality by comparing the association between HbA1c 
and cancer incidence by time since study entry (0–6 
months, 6 months–2 years, and 2+ years) for the primary 
outcomes. Third, we assessed changes in the association 
between HbA1c and risk of the primary cancer outcomes 
at each stage of confounder adjustment to identify 
which variables appeared to have greater impact on the 
observed results. Finally, we estimated the association 
between having a type 2 diabetes diagnosis at baseline 
and risk of cancer incidence, not adjusting for HbA1c, to 
determine if we could replicate established associations 
from multiple previous studies.2 If similar associations 
were observed to those reported previously, then this 
would provide reassurance that potential null findings 
for the effect of HbA1c were unlikely to be explained 
by a relatively healthier population as has been found 
in UK Biobank compared with the general population.13 
In post hoc analyses, we adjusted estimates for premeno-
pausal breast cancer with maternal age at first live birth, 
which was available on 60% of the modeled sample. We 
also tested the robustness of the choice of timescale by 
Figure 1 Study flow chart. *We used a previously validated 
algorithm to identify diagnosed type 1 and 2 diabetes, 
which included exposure to glucose- lowering therapies. A 
small number of individuals (n=128) on metformin for other 
indications were also excluded from some modeling. BMI, 
body mass index; HbA1c, glycated hemoglobin.
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comparing estimates from primary analyses to those from 
models using age as the timescale.
RESULTS
Cohort description
Of the 502 536 participants in the UK Biobank, 35 080 
were excluded for having a history of cancer at the 
baseline assessment. A further 89 203 were excluded for 
having missing data on at least one of the covariates of 
interest, leaving a total of 378 253 participants eligible to 
contribute to analysis (figure 1). Of these, 349 825 (93%) 
had normal, 15 648 (4%) had prediabetic and 12 780 
(3%) had diabetic levels of HbA1c at baseline. Individ-
uals with higher HbA1c (prediabetic or diabetic) were 
observed to have higher median BMI, were less likely 
to do moderate or vigorous physical activity, were more 
deprived and more likely to be of non- white ethnicity 
compared with those with normal HbA1c (table 1). Of 
the 378 253 eligible participants, 17 485 (5%) reported 
a diabetes diagnoses or were on metformin at baseline. 
Characteristics of the 360 768 participants without diag-
nosed diabetes or on metformin at baseline are provided 
in online supplementary table S1.
Cancer incidence
Among 378 253 individuals with median follow- up time of 
7.1 years (IQR 6.4–7.7 years) for a total 2 425 635 person- 
years (PY), 21 172 (5.6%) had an incident cancer diag-
nosis. Age- standardized rates per 1000 PY for any cancer 
in those with normal, prediabetic, and diabetic levels of 
HbA1c were 8.65 (95% CI 8.54 to 8.77), 10.69 (95% CI 
10.04 to 11.28), and 9.89 (95% 9.23 to 10.49), respectively 
(table 2). Age- standardized rates per 1000 PY of prostate 
cancer were lower among individuals with diabetic levels 
of HbA1c (2.84, 95% CI 2.44 to 3.24) than those with 
normal HbA1c (4.09, 95% CI 3.96 to 4.21). Conversely, 
rates of colorectal cancer per 1000 PY were higher among 
individuals with diabetic levels of HbA1c (1.34, 95% CI 
1.07 to 1.62) than those with normal HbA1c (1.01, 
95% CI 0.97 to 1.05). For lung and postmenopausal 
breast cancer, rates were similar between those with 
normal and diabetic levels of HbA1c but elevated among 
those with prediabetic levels of HbA1c. Similar rates of 
premenopausal breast cancer were observed among 
those with normal and diabetic levels of HbA1c but lower 
among those with prediabetic levels of HbA1c; however, 
there were only five cases in this group. Incidence rates 
did not meaningfully change among patients without a 
baseline diabetes diagnosis or exposure to metformin 
(online supplementary table S2) or rates including the 
first 6 months after baseline (online supplementary table 
S3).
Adjusted analyses
Overall, there was no clear evidence of an association 
between HbA1c and incidence of prostate, colorectal, 
and lung cancer after adjustment for a comprehensive 
range of confounders (figure 2A). There was evidence of 
increased risk of premenopausal breast cancer at lower 
levels of HbA1c (HR 1.27, 95% CI 1.00 to 1.60 for 25 
vs 35 mmol/mol) and decreased risk at higher levels of 
HbA1c (HR 0.71, 95% CI 0.54 to 0.94 for 45 vs 35 mmol/
mol; HR 0.50, 95% CI 0.26 to 0.93 for 55 vs 35 mmol/
mol). There was weak evidence of an association between 
lower HbA1c and increased risk of postmenopausal breast 
cancer (HR 1.19, 95% CI 0.99 to 1.43 for 25 vs 35 mmol/
mol). Results were broadly similar when restricting to 
individuals without a diabetes diagnosis or exposure to 
glucose- lowering medication at baseline (figure 2B). In 
this subgroup analysis, there was some suggestion of an 
increased risk of colorectal cancer with increasing HbA1c 
(HR 1.21, 95% CI 0.98 to 1.50 for 55 vs 35 mmol/mol), 
though there were only 24 events in this range of HbA1c.
Among the 12 less common cancers investigated, with 
the exception of pancreatic and uterine cancer, there 
was no clear pattern of association between HbA1c and 
cancer incidence, although CIs were wide due to limited 
numbers of events (online supplementary figure S1). 
There was relatively strong evidence that HbA1c was 
positively associated with pancreatic cancer, whereby low 
HbA1c was associated with lower cancer risk (HR 0.39, 
95% CI 0.25 to 0.62 for 25 vs 35 mmol/mol) and high 
HbA1c was associated with elevated cancer risk (HR 1.55, 
95% CI 1.22 to 1.98 for 55 vs 35 mmol/mol). There was 
also evidence that low HbA1c was associated with lower 
risk of uterine cancer (HR 0.52, 95% CI 0.34 to 0.79 for 
25 vs 35 mmol/mol). These findings remained when 
excluding those with a diabetes diagnosis at baseline 
(online supplementary figure S2).
Sensitivity analyses
For the majority of cancers, there was very little qualitative 
change after excluding individuals with smoking history 
at baseline, though in some cases, such as the inverse 
association with premenopausal cancer, statistical signifi-
cance was lost (online supplementary figure S3). Fitting 
the model separately by time since study entry did not 
suggest that any of the observed results were influenced by 
reverse causation (online supplementary figures S4- S5). 
Adjusting for diagnosed diabetes at baseline consistently 
had a large impact on the observed associations with all 
primary cancer outcomes, in addition to age adjustment 
for prostate and colorectal cancer and smoking and 
alcohol adjustment for lung cancer (online supplemen-
tary figures S6- S10). All other confounder adjustments 
tended to make relatively minor, incremental differences. 
When comparing cancer risk in people with and without 
diagnosed type 2 diabetes at baseline, we found evidence 
of decreased risk of prostate cancer (HR 0.75, 95% CI 
0.66 to 0.86) and increased risk of colorectal cancer (HR 
1.23, 95% CI 1.05 to 1.44), pancreatic cancer (HR 1.59, 
95% CI 1.21 to 2.09), uterine cancer (HR 1.52, 95% CI 
1.13 to 2.04), and bladder cancer (HR 1.60, 95% CI 1.21 
to 2.11) (online supplementary figure S11). In post hoc 
analyses, while variance in estimates increased due to 
the lower number of events, the shape of the association 
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Table 1 Baseline characteristics of 378 253 eligible UK Biobank participants
<6% or 
<42 mmol/mol
6%–6.4% or 
42–47 mmol/mol
≥6.5% or 
≥48 mmol/mol
N 349 825 15 648 12 780
Age at baseline assessment, years (median (IQR)) 57.0 (49.0 to 63.0) 61.0 (56.0 to 65.0) 61.0 (54.0 to 65.0)
Female (N %) 189 945 (54.3) 7401 (47.3) 4644 (36.3)
Ethnicity
  White European 336 172 (96.1) 13 812 (88.3) 11 288 (88.3)
  South Asian 3845 (1.1) 590 (3.8) 627 (4.9)
  African Caribbean 3535 (1.0) 639 (4.1) 399 (3.1)
  Mixed or other 6273 (1.8) 607 (3.9) 466 (3.6)
Townsend deprivation index quintile
  Least deprived 74 442 (21.3) 2693 (17.2) 1987 (15.5)
  Second least deprived 73 142 (20.9) 2853 (18.2) 2162 (16.9)
  Median deprivation level 71 721 (20.5) 2914 (18.6) 2337 (18.3)
  Second most deprived 69 056 (19.7) 3309 (21.1) 2693 (21.1)
  Most deprived 61 464 (17.6) 3879 (24.8) 3601 (28.2)
Smoking status
  Never smoker 245 290 (70.1) 9109 (58.2) 7417 (58.0)
  Former smoker 80 703 (23.1) 4786 (30.6) 4273 (33.4)
  1–9 CPD 5144 (1.5) 240 (1.5) 141 (1.1)
  10–19 CPD 10 107 (2.9) 750 (4.8) 453 (3.5)
  20–29 CPD 6814 (1.9) 580 (3.7) 355 (2.8)
  30+ CPD 1767 (0.5) 183 (1.2) 141 (1.1)
Alcohol use
  Daily or almost daily 74 105 (21.2) 2562 (16.4) 1853 (14.5)
  Three or four times a week 86 080 (24.6) 2682 (17.1) 1965 (15.4)
  Once or twice a week 91 703 (26.2) 3851 (24.6) 3063 (24.0)
  One to three times a month 38 642 (11.0) 1991 (12.7) 1684 (13.2)
  Special occasions only 35 760 (10.2) 2634 (16.8) 2288 (17.9)
  Never 23 535 (6.7) 1928 (12.3) 1927 (15.1)
Days per week spent doing moderate physical activity
  None 43 485 (12.4) 2573 (16.4) 2585 (20.2)
  1–2 80 980 (23.1) 3329 (21.3) 2812 (22.0)
  3–4 53 350 (15.3) 2278 (14.6) 1766 (13.8)
  5+ 172 010 (49.2) 7468 (47.7) 5617 (44.0)
Days per week spent doing vigorous physical activity
  None 122 655 (35.1) 7073 (45.2) 6287 (49.2)
  1–2 108 371 (31.0) 4164 (26.6) 3158 (24.7)
  3–4 50 518 (14.4) 1772 (11.3) 1319 (10.3)
  5+ 68 281 (19.5) 2639 (16.9) 2016 (15.8)
Days per week walked for >10 min
  None 7287 (2.1) 504 (3.2) 592 (4.6)
  1–2 31 086 (8.9) 1523 (9.7) 1279 (10.0)
  3–4 27 730 (7.9) 1269 (8.1) 1103 (8.6)
  5+ 283 722 (81.1) 12 352 (78.9) 9806 (76.7)
Days per week with intake of processed meats
Continued
 o
n
 August 28, 2020 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2020-001600 on 27 August 2020. Downloaded from 
6 BMJ Open Diab Res Care 2020;8:e001600. doi:10.1136/bmjdrc-2020-001600
Epidemiology/Health services research
between HbA1c and premenopausal breast cancer 
observed in primary analyses remained after adjusting for 
age at first live birth (online supplementary figure S12). 
Finally, models using age as the timescale did not change 
conclusions from models using time since baseline as the 
timescale (online supplementary figure S13).
CONCLUSIONS
In this study of 378 253 adults with 21 172 incident cancer 
events over an average 7 years of follow- up, we found no 
consistent evidence that higher HbA1c was associated 
with incident cancer risk among nearly all of the 16 
cancer types investigated apart from pancreatic cancer. A 
novel finding was an inverse association between HbA1c 
and premenopausal breast cancer, which persisted when 
people with diagnosed diabetes or on glucose- lowering 
medications were excluded. This study is the largest study 
to date to investigate the association between HbA1c and 
multiple specific cancers adjusting for a wide range of 
demographic, lifestyle, and clinical factors. There was 
no suggestion that any observed associations (or lack 
thereof) with cancer incidence were explained by reverse 
causality.
We examined the associations between cancer risk and 
having a diagnosis of type 2 diabetes at baseline and found 
positive associations with colorectal, pancreatic, uterine 
and bladder cancer, and a negative association with pros-
tate cancer. This is consistent with previous research, 
alleviating concerns around UK Biobank participants 
being healthier than the general population.13 Interpre-
tation of previous studies of individual cancer incidence 
across the entire glycemic spectrum has been limited by 
small numbers. Much of our understanding of this asso-
ciation therefore comes from dichotomized comparisons 
of people with and without diagnosed type 2 diabetes. 
We were able to take these analyses further, exploring 
associations across the full glycemic range. Exclusion of 
people with diagnosed diabetes or prescribed metformin 
for other indications addresses the uncertainties around 
effects of glucose- lowering medication.3 For the most 
part, this had little impact on associations. Thus, apart 
from known associations with pancreatic cancer,14 we 
were not able to demonstrate any consistent link between 
higher HbA1c and risk for cancer that would support a 
hyperglycemia associated mechanism for cancer risk.
We found a novel inverse association between HbA1c 
and premenopausal breast cancer, whereby increased 
<6% or 
<42 mmol/mol
6%–6.4% or 
42–47 mmol/mol
≥6.5% or 
≥48 mmol/mol
  None 32 903 (9.4) 1161 (7.4) 837 (6.6)
  <1 108 194 (30.9) 4294 (27.4) 3053 (23.9)
  1 101 933 (29.1) 4626 (29.6) 3744 (29.3)
  2–4 93 383 (26.7) 4822 (30.8) 4390 (34.4)
  5+ 13 412 (3.8) 745 (4.8) 756 (5.9)
Number of fruits or vegetables consumed per day
  None 10 712 (3.1) 685 (4.4) 501 (3.9)
  1–2 61 487 (17.6) 2831 (18.1) 2325 (18.2)
  3–4 102 465 (29.3) 4527 (28.9) 3742 (29.3)
  5+ 175, 161 (50.1) 7605 (48.6) 6212 (48.6)
  BMI at baseline, kg/m2 (median (IQR)) 26.4 (23.9 to 29.4) 29.7 (26.7 to 33.5) 30.8 (27.5 to 34.9)
  HbA1c at baseline, mmol/mol (median (IQR)) 34.7 (32.4 to 37.0) 43.7 (42.7 to 45.2) 56.6 (51.4 to 65.3)
Comorbidities reported at baseline
  Any cardiovascular disease 40 841 (11.7) 3660 (23.4) 3446 (27.0)
  Type 1 diabetes 43 (0.0) 112 (0.7) 1143 (8.9)
  Type 1 diabetes 3277 (0.9) 3693 (23.6) 9089 (71.1)
Medications reported at baseline
  Metformin 1258 (0.4) 2049 (13.1) 6611 (51.7)
  Other oral antidiabetic therapy 409 (0.1) 824 (5.3) 3312 (25.9)
  Insulin 257 (0.1) 381 (2.4) 3107 (24.3)
  Hormone replacement therapy 14 517 (4.2) 321 (2.1) 222 (1.7)
  Oral contraceptives 5631 (1.6) 60 (0.4) 92 (0.7)
BMI, body mass index in kilograms per square metre (kg/m2); CPD, cigarettes smoked per day; HbA1c, glycated hemoglobin.
Table 1 Continued
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HbA1c was associated with decreased risk of cancer, 
that were not attributed to differences in demographic 
characteristics, BMI, or lifestyle factors. There have been 
previous suggestions that glucose- lowering therapies, 
particularly metformin, are associated with lower risk of 
breast cancer though concerns over bias were raised.15 16 
Subsequent studies have found no such evidence.17 In 
our current analysis, we demonstrated the relationship 
between HbA1c and premenopausal breast cancer could 
not be attributed to glucose- lowering therapy since the 
association was also found in a model excluding those 
with diagnosed diabetes or on metformin. Previous 
studies have found that younger maternal age at first 
birth increases risk of hyperglycemia and diabetes.18 19 In 
contrast, older maternal age at first birth is one of the 
key risk factors for premenopausal breast cancer, a factor 
that does not appear to contribute to postmenopausal 
cancer.20 Low normal glycemia could be acting as a proxy 
for older age at first birth, potentially accounting for the 
inverse association between hyperglycemia and premeno-
pausal breast cancer risk. However, after adjusting esti-
mates for maternal age at first live birth in post hoc 
analyses, the inverse association observed in primary 
analyses remained. Another possible mechanism could 
be that women with diabetes or higher BMI (ie, those 
with elevated HbA1c) are more engaged with healthcare 
services resulting in earlier detection of breast cancer; 
however, this information is not available in UK Biobank.
We had several incidental findings in sensitivity analyses. 
For example, after excluding individuals with diagnosed 
diabetes or on glucose- lowering medications, there was 
a suggestion that increased HbA1c was associated with 
elevated risk of incident stomach cancer. This finding is 
consistent with a previous study of 2603 individuals that 
accounted for confounding factors including BMI and 
alcohol intake21 but contradicts null or potentially under-
powered findings from two larger studies by Travier et al22 
and Miao Jonasson et al23 (n=46 575 and n=25 276, respec-
tively). Caution should be used when interpreting this 
and findings from other sensitivity analyses since they 
were not observed in primary analyses. There remains 
the possibility that the observations occurred simply by 
chance due to the number of comparisons we performed 
in sensitivity analyses or perhaps due to collider bias 
introduced by excluding populations.
The most recent systematic review of associations 
between HbA1c and cancer risk included 19 studies,4 
the largest of which analyzed 46 575 individuals with 634 
cancer events.22 While the authors found no evidence of 
an association between HbA1c and any of the cancers 
also included in the present study, the number of site- 
specific cancer events were low. A more recent study 
by Goto et al24 followed 29 629 individuals with HbA1c 
measurements of whom only 6% had an existing diabetes 
diagnosis. The authors found an overall increased risk of 
cancer with increasing HbA1c, which was not observed 
after excluding events in the first 3 years of follow- up. A 
large study by Dankner et al7 included 440 000 individuals 
with diagnosed diabetes from a large insurance database. 
With over 26 000 cancer events, they found no association 
between HbA1c and overall cancer risk but did observe a 
positive association with pancreatic cancer and negative 
association with prostate cancer. We confirm an associa-
tion with pancreatic cancer; however, we show that any 
protective effect of HbA1c on prostate cancer is lost after 
Figure 2 Associations between glycated hemoglobin 
(HbA1c) and incidence of common cancers in the UK 
Biobank. HRs from Cox proportional hazards models, 
adjusted for age at study entry, sex (except sex- specific 
cancers), ethnicity, deprivation, body mass index, 
physical activity, cardiovascular disease, diagnosed 
diabetes, smoking status, alcohol consumption, use of 
oral contraceptives and hormone replacement therapy 
(postmenopausal breast only), and processed meat and 
fruit and vegetable intake (colorectal only). Reference 
HbA1c=5.4% (35 mmol/mol). Results shown including 
(left) and excluding (right) those with diagnosed diabetes 
at baseline. Significance tests include p overall for test of 
overall association, p non- linear for test of linearity, p non- PH 
for test of proportional hazards.
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adjustment, namely for diagnosed diabetes. Danker et al 
were not able to adjust for variables included in the UK 
Biobank, including BMI, physical activity, and underlying 
cardiovascular disease, and only included individuals 
with diagnosed diabetes thus effects may be confounded 
by exposure to glucose- lowering therapies or some other 
unmeasured factor.
Our study has several key strengths, particularly a large 
sample size, the inclusion of individuals with and without 
diagnosed diabetes and as such not exposed to any 
glucose- lowering medications, a long follow- up window, 
and highly detailed covariate data with small proportions 
of missingness. We ascertained cancer outcomes from 
highly reliable linked UK cancer registry data covering all 
treated cancers in the National Health Service. We also 
acknowledge some important limitations. We approxi-
mated menopausal status, meaning that there may be 
some misclassification of premenopausal or postmeno-
pausal breast cancers; however, previous studies have 
suggested that such proxies produce valid incidence 
rates.10 The overall healthier population contributing 
to the UK Biobank13 meant that we observed relatively 
low cancer incidence rates, and as such, the power of our 
analysis was likely affected. Although the underlying inci-
dence rates and exposure distributions may not be repre-
sentative of the UK population, the associations observed 
between HbA1c and cancer incidence are unlikely to be 
biased.25 This is supported by our sensitivity analysis repli-
cating associations between type 2 diabetes and cancer 
incidence that are consistent with a recent umbrella 
review.2 Lastly, it is possible that although we adjusted for 
a wide range of confounders, some residual confounding 
may remain. We were also unable to look at the effect of 
medication use in those with diagnosed diabetes as we 
lacked longitudinal prescription data.
In conclusion, apart from pancreatic cancer, we 
did not demonstrate any independent positive associ-
ation between HbA1c and risk for cancer in this large 
sample of UK adults. We identified an inverse associa-
tion between HbA1c and premenopausal breast cancer 
unlikely to be attributed to antidiabetic therapies. These 
findings suggest that concerns around the potential for 
a cancer- inducing, direct effect of hyperglycemia may be 
misplaced. Future research should explore other poten-
tial mechanisms that have been hypothesized, including 
genetic risk factors and chronic inflammation.
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